Blocking USP7 May Slow Kidney Scarring in CKD – Hope

Credibility

Interest

Share:2 min read

Key Takeaway

Scientists found that blocking a protein called USP7 can reduce kidney scarring by restoring a protective brake on a growth pathway, which could help slow chronic kidney disease.

What They Found

The study showed USP7 is higher in kidneys with chronic disease and this matches areas of scarring and worse kidney function. In mice, removing or blocking USP7 reduced activation of scar-forming cells and lowered the buildup of scar tissue. USP7 acts like a shield that protects another protein, KDM5B, from being broken down; KDM5B then turns down the gene for TSC1. TSC1 normally acts like a brake on the mTOR pathway, which is a cell growth engine that can drive scarring when stuck 'on.' So, blocking USP7 lets KDM5B get removed, TSC1 levels recover, and the mTOR engine slows down, reducing kidney fibrosis.

Who Should Care and Why

People with MS who have or may develop kidney problems should care because kidney scarring (fibrosis) can lead to long-term kidney decline like other chronic diseases do. Caregivers and healthcare providers should notice that this study points to a new target (USP7) that might become a future treatment to slow scarring, similar to fixing an overheated engine so the car runs better longer. Patients on multiple medications or with risk factors for kidney damage might benefit in the future if therapies targeting USP7 are developed, because it could protect kidney function. For everyday life, this research supports the importance of monitoring kidney health and talking with doctors about new treatments as they become available. Researchers and clinicians may use these findings to design safer drugs that restore the kidney's natural brakes on scarring.

Important Considerations

This research was done in mice and lab tests, not yet in people, so we do not know if USP7 blockers will be safe or effective for patients. The study focuses on one way scarring happens, but kidney fibrosis is complex and other pathways may also need treatment. It may take years of further trials before any new therapy based on these findings becomes available for patients.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research MS Genetics MS Progression

Article Topics:

DeubiquitinationHistone methylationKidney fibrosisLysine-specific demethylase 5B (KDM5B)Ubiquitin-specific protease 7 (USP7)

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Molecular biomedicine often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News